COMMUNIQUÉS West-GlobeNewswire
-
Inteleos 2026 Leadership Elections Accelerate Vision for Global Healthcare
03/03/2026 -
PathAI Receives U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI-Powered Pathology Solution to Transform Dermatopathology Workflow
03/03/2026 -
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
03/03/2026 -
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
03/03/2026 -
Tekton Research Appoints Dr. Jara McDonald as Executive Medical Director to Support Continued Growth in Cardiometabolic Research
03/03/2026 -
LiveWorld Launches Integrated GEO, AIO and SEO Search Optimization for Healthcare and Pharma Brands
03/03/2026 -
Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
03/03/2026 -
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
03/03/2026 -
Spryte Medical Announces First Participants Enrolled in the INSYTE Trial at Baptist Health Jacksonville
03/03/2026 -
Human Appeal hosts global Grand Iftars, providing over 250,000 meals for vulnerable people this Ramadan
03/03/2026 -
Exagen Inc. to Participate in Upcoming Investor Conferences
03/03/2026 -
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
03/03/2026 -
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
03/03/2026 -
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
03/03/2026 -
TOMI Environmental Solutions Appoints Total Clean Air as Preferred European Partner for SteraMist iHP Decontamination Technology
03/03/2026 -
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
03/03/2026 -
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
03/03/2026 -
NDT Pharmaceuticals Highlights Enhanced Omni-Channel Positioning; Sets Stage for 2026 Growth with Strategic Marketing Expansion
03/03/2026 -
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
03/03/2026
Pages